Donate For Public and Patients Store Search

F118 - Skin and Systemic Malignancy

Monday, March 4; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify skin manifestations of systemic malignancy presenting as various paraneoplastic dermatoses, genodermatoses, and skin metastases, and summarize their management, including special reference to alternative/complementary medicine options.
  • Recognize the spectrum of cutaneous effects of therapeutics, emphasizing recent immunotherapy agents, used to treat systemic malignancies.
  • Summarize the malignancy risk of dermatologic therapeutics.


The rich intersection between skin and systemic malignancy is the focus of this forum, which both explores the spectrum of how skin reflects systemic malignancy and its treatment, and also assesses the malignancy risk of therapies for dermatologic conditions. Special attention is given to how alternative and complementary medicine might be used to help manage both paraneoplastic dermatoses and adverse therapeutic reactions. Additional emphasis will be given to updated understanding of genodermatoses. The use of patient cases and audience participation will facilitate session attendees’ ability to better formulate practical plans for appropriate work-up and therapy in patients with suspected skin signs of systemic malignancy, and to better manage mucocutaneous effects of systemic therapy. This forum is designed for both clinicians in practice and those in training.


  • Armstrong, April W., MD, MPH: AbbVie – A(H), C(H), Data Safety Monitoring Board(H), I(Grants/Research Funding), SP(H); Amgen – A(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – C(H), I(Grants/Research Funding); Demira – I(Grants/Research Funding); Dermavant Sciences – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – C(H); Genzyme Corporation – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), SP(H); Janssen-Ortho Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Merck & Co., Inc – A(H); Modernizing Medicine – C(H); NIH – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Parexel – Data Safety Monitoring Board(H); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H);
  • Dyer, Jonathan A., MD: Allergan, Inc – I(NC); Scioderm – I(NC);
  • Lio, Peter A., MD: AbbVie – C(Fees), I(Grants/Research Funding); Altus Labs – A(SO); Amyris, Inc. – C(Fees); AOBiome, LLC – I(Grants/Research Funding); Arbonne – A(H); Burt's Bees – C(Fees); Dermavant Sciences – A(H); Dermira – C(Fees); DermTap, Inc. – A(SO); DermVeda – A(SO); Eli Lilly and Company – C(Fees); Exeltis – C(Fees); Franklin BioScience – C(SO); gpower, inc. – A(H); IntraDerm Pharmaceuticals – A(H); Johnson & Johnson Consumer Products Company – A(H); Kiniksa Pharmaceuticals, Ltd. – C(H); L'Oreal USA Inc. – C(H); La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis – I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – SP(H); LearnHealth/LearnSkin – SH(SO); LEO Laboratories Ltd (LEO Pharma) – C(Fees); Medable – SH(SO); Menlo Therapeutics – A(H); Micreos Human Health B.V. – A(SO); Modernizing Medicine – A(NC), SH(SO); National Eczema Association – A(NC); Odeza LLC – C(SO); Pfizer Inc. – SP(H); Pierre Fabre Dermatologie – SP(H); Realm Therapeutics – A(H); Regeneron – A(Fees), I(Grants/Research Funding), SP(Fees); Sanofi US Services – A(H); Syncere Skin Systems – A(SO); Theraplex – C(Fees), O(IP); TopMD – C(Fees); UCB – A(H); Unilever – C(Fees); Verrica Pharmaceuticals Inc – A(H);
  • Liu, Vincent, MD: no financial relationships exist with commercial interests.
  • Pugliese, Silvina, MD: no financial relationships exist with commercial interests.
Monday, March 4
9:00 AM
Dr. Liu / Introduction/Overview
9:03 AM
Dr. Liu / Paraneoplastic Dermatoses & Cutaneous Metastases
9:25 AM
Dr. Dyer / Genodermatoses- Diagnosis & Management
9:45 AM
Dr. Lio / Complementary Medicine and Skin Malignancy
10:05 AM
Dr. Armstrong / Risks of Malignancy of Dermatologic Therapeutics
10:30 AM
Dr. Pugliese / Cutaneous Effects of Therapies for Systemic Malignancy
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 140A
  • CME Credits
  • Type
  • April W. Armstrong, MD, MPH, FAAD - Handout
  • Jonathan A. Dyer, MD, FAAD - Handout
  • Peter A. Lio, MD, FAAD
  • Silvina Pugliese, MD, FAAD